| Filed On | Filing |
|---|---|
| 06 Oct 2026 | Proxy statement: special meeting on November 10, 2026 |
| 02 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated October 1, 2026, which is incorporated herein by reference. The Company intends to use the presentati... |
| 23 Sep 2026 | PRE 14A |
| 11 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
AMENDMENT TO THETHIRD AMENDED AND RESTATED BY-LAWSofDARÉ BIOSCIENCE, INC. |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated September 9, 2026, which is incorporated herein by reference. The Company intends to use the presenta... |
| 04 Sep 2026 | 424B3 |
| 03 Sep 2026 | EFFECT |
| 28 Aug 2026 | SCHEDULE 13G |
| 26 Aug 2026 | S-1 |
| 24 Aug 2026 | SCHEDULE 13G |
| 20 Aug 2026 | D |
| 19 Aug 2026 | 253G2 |
| 17 Aug 2026 | 424B5 |
| 17 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Jul 2026 | 8-K: Regulation FD Disclosure |
| 17 Jul 2026 | 253G2 |
| 17 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
Loading...
